Sales Already Growing As Vascepa Secures Cardio Approval
Fish Oil Derivative Seen As Biggest Advance In Decades
Company forecasts 2020 sales as high as $700m after regulator grants broad label.
You may also be interested in...
Teva was in position to introduce further generic competition to Amarin’s Vascepa following legal setbacks for the originator. However, the firm’s ANDA has since been listed as discontinued.
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
Amarin has confirmed that it plans to take its legal battle over Vascepa all the way to the US Supreme Court, as it seeks to overturn a ruling that has already allowed Hikma to launch its generic rival.